ICE方案治疗晚期非小细胞肺癌的临床观察

Clinical study on efficacy of patients with non-small cell lung cancer treated with ICE regimen

目的:观察异环磷酰胺(IFO)、顺铂(DDP)、依托泊苷(Vp16)联合化疗治疗晚期非小细胞肺癌(nonsmall cell lungcancer,NSCLC)的效果和不良反应。方法:IFO2g,持续4h静脉滴入,d1～d3;DDP25mg/m2,静脉滴入,d1～d3;Vp1680mg/m2,静脉滴入,d1～d3。每28d为1个周期。结果:48例总有效率为43.75%,鳞癌27例有效率为59.26%,腺癌21例有效率为23.81%,两者差异有统计学意义,u=2.783,P=0.0054;中位生存期8.6个月,1年生存率为25%,2年生存率为9.1%;不良反应主要是骨髓抑制,其次为消化道反应和脱发。结论:ICE方案治疗NSCLC可获得较好的远近期效果(鳞癌优于腺癌),但需注意其易出现骨髓抑制的不良反应。

OBJECTIVE： To investigate the efficacy and toxicity of patients with non small cell lung cancer （NSCLC） treated with cisplatin based combination chemotherapy regimens：ifosfamide, cisplatin and etoposide regimen （ICE）. METHODS： Ifosfamide was adminis tered intravenously in a dose of 2 g for four hours from Day 1 to Day 3. DDP was given in a dose of 25 mg/m^2 intravenously （Vp- 16 80 mg/ m^2） from day 1 to day 3. This combination was repeated every 28 days. RESULTS：The response rate for the whole group was 43.75%. The response rate of squamaous cancer of 27 cases was 59.26% the response rate of glandular cancer of 21 cases was 23.81%. There was a significant difference between them,u=9. 783,P=0.005 4. Median survival of response was 8.6 months, the survival rate of one year was 25%, the one of two years was 9. 1%. The major toxicity was myelosupression,and other toxicities included loss of appetite, nausea/vomiting, stomatites and alopecia. CONCLUSIONS：ICE is a good long-dated effective regimen for the patients with NSCLC, but meanwhile, it is easy to have the toxicity of myelosupression.